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PrivacyData sharing is increasingly becoming an essential component of clinical practice and biomedical research. The
debate has shifted from whether or not to exchange data to how best to achieve optimal sharing. This raises
new ethical and legal challenges, particularly with regard to consent and privacy. This article discusses recent
developments in the formulation of best practice guidelines for data sharing. Particular attention is focused on
the Global Alliance for Genomics and Health (GA4GH) draft Framework of Conduct for Data Sharing.
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As the power of integrating multiple sources of data to progress
understanding of human health is becoming increasingly understood,
there is a general recognition that the next phase of personalised medi-
cine will see acceleration in data sharing to link genome scans to clinical
data.1 In the clinical context, the move to electronic health records and
electronically stored data provides opportunities to use and share data
to better understand disease and illness, inform treatment choices and
patient care and improve health outcomes.2 In the research context, orga-
nisations such as the International Cancer Genome Consortium (ICGC)3
and, more recently, the Global Alliance for Genomics and Health
(GA4GH)4 have embraced policies and plans to proselytise and promote
the exchange of clinical data not only amongst Consortium and Alliancede of Conduct for International
et al (2009) ‘Data Sharing in
cs 10(5):331–335.
Care’, New England Journal of
ing Data to Improve Health
pen access article under the CC BY-Nmembers but also more widely in research and clinical care. The over-
arching aim is to drive the research into the translation phase where the
clinical data will be matched with genomic data to inform the develop-
ment of treatments and medications.
‘Data sharing’ can take many different forms; e.g. patients agreeing
to share their genomic and/or clinical data with researchers;
researchers sharing their preliminary data with other researchers;
biobanks and other holders of specimens and data sharing their re-
sources with researchers in other countries. This paper encompasses
all such forms of data sharing, but is particularly focused on larger
scale data sharing involving multiple players, across jurisdictions.
The importance of data sharing has become something of a ‘mantra’5
amongst medical and health researchers. This mantra has been
fashioned by government initiatives to promote the new knowledge
economy.6 As an example in the clinical context, the Strategy for UK
Life Sciences states:5 Jasny B (2013). ‘Realities of Data Sharing Using the GenomeWars as a Case Study— an
Historical Perspective and Commentary’, EPJ Data Science 2:1 doi:10.1140/epjds13.
6 Academy of Medical Sciences UK (2010), Review of the Regulation and Governance of
Medical Research, http://www.acmedsci.ac.uk/.
C-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
17 Allen, C Joly, Y and Grandos Morena, P (2013). ‘Data Sharing, Biobanks and Informed
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the NHS. There is huge potential to better support the adoption and
diffusion of innovation, to access patient data to inform the develop-
mental phase, and to involve patients in trials and early access schemes
for the treatment of chronic diseases, such as cancer.'7
The sheer volumes of data are creating mountainous storage and
download exchange challenges.8 The debate has shifted fromwheth-
er or not to share data for research, together with the accompanying
technical challenges, to how data exchange should be done in order
to add value to the research endeavour whilst protecting research
participants.9 However, like genomic science itself, data sharing in
this arena has not proven to be easy and a long road lies ahead.
There is recognition of the need for a risk/beneﬁt analysis; whilst
data sharing is seen as essential to promote the goals of the genome
era, care must be taken to minimise the risk of harm from such data
sharing. Of its nature, genetic data has some particular characteris-
tics: genetic information is ubiquitous, permanent and unalterable.
Even when de-identiﬁed, genetic data is always inherently identiﬁ-
able, and this applies also to person's whole genome sequence, so
special protections are required if such data is to be linked to other
sensitive information.10 As mechanisms for data protection become
increasingly sophisticated, risk arises from new strategies to out-
ﬂank protections.11 Once data is released into the public domain,
neither participants nor researchers can control its use, or the possi-
bility of that data being linked to other data sets.12 The pitfalls for
data sharing are many, with privacy, industry–academia divides,
distinction between ﬁrst and third world technological capacities,
and diverse researcher, clinical and institutional practices amongst
the regulatory hurdles across national borders. 13 Other challenges
include workforce and infrastructure limitations but one of the
greatest challenges is overcoming policy issues.14 Kaye has identiﬁed
four particular areas for attention:
'The difﬁculties of acknowledging individual contributions to the
generation of data; the way that these policies change the responsibili-
ties towards participants; the implications that this has for maintaining
public trust; and the new mechanisms that have been developed for
oversight of access to data.'15
A key issue in this context is the level of informed consent for data
sharing. Potentially there are a range of models – at one extreme – no
consent or notice, or notice only, or ‘opt-out’ rights or ‘opt in’ rights or
other forms of express consent. Because of the scale of genomic data
and very nature of biobanks as platforms for research undertaken over
a period of time, there has been considerable support for a ‘broad
consent’ model whereby participants give agreement to the use of
their samples and information, in a de-identiﬁed form, for future as
yet unspeciﬁed research, subject to normal ethics committee review
and this approach is endorsed in a number of jurisdictions.16 There are7 Academy of Medical Sciences UK (2010), Review of the Regulation and Governance of
Medical Research, http://www.acmedsci.ac.uk/.
8 Google, Amazon andMicrosoft are active in this new cloud commercial environment.
9 Ohno-Machado, L (2012) ‘To Share or not to Share: That is Not the Question’ Science
Translation Medicine 4:1–4.
10 Ohno-Machado, L (2012) ‘To Share or not to Share: That is Not the Question’ Science
Translation Medicine 4:1–4.
11 Erlich Y and Narayanan A, (2014) ‘Routes for Breaching and Protecting Genetic Priva-
cy’ Nature Review Genetics 15:409.
12 Kaye J et al (2009). ‘Data Sharing in Genomics— Re-shaping Scientiﬁc Practice’,Nature
Genetics 10(5):331–335.
13 Jasny B (2013). ‘Realities of Data Sharing Using the Genome Wars as a Case
Study − an Historical Perspective and Commentary’, EPJ Data Science 2:1 doi:10.1140/
epjds13.
14 Ohno-Machado, L (2012) ‘To Share or not to Share: That is Not the Question’ Science
Translation Medicine 4:1–4.
15 Kaye J et al (2009). ‘Data Sharing in Genomics— Re-shaping Scientiﬁc Practice’,Nature
Genetics 10(5):331–335.
16 Otlowski, M (2012). ‘Tackling Legal Challenges Posed by Population Biobanks:
Reconceptualising Consent Requirements’ Medical Law Review 20, 191–226.some commentators, however, who contest that this can ever be an
effective consent.17
Kaye has promoted technologically aided ‘dynamic consent’ as part
of a more sophisticated genomic data management system: i.e. ‘a
personalised, digital interface that connects researchers and partici-
pants,’ facilitating ‘two-way communication to stimulate a more
engaged and informed.. participant population where individuals can
tailor and manage their own consent and preference.’18 There is
continuing debate about optimal consent models for biobanks and
large data sharing platforms19; for the purposes of this paper, as a
minimum, broad consent should be obtained fromparticipants to future
genomic research and for data sharing, as a precondition for data
sharing.
The development of data sharing policies and practices will require
the development of standards.20 This article examines how far an inter-
national code or framework of ethics may contribute to changing
attitudes and practices towards more responsible and secure sharing
of research and clinical data.
2. Background to data sharing
There has been major expansion of globalisation of research in the
‘Genome Era’. This has prompted a range of international organisations
to enter the arena of international ethics standard setting. Examples are
UNESCO (and their trilogy of Declarations on the Human Genome and
Human Rights, 1997; Human Genetic Data 2005; and Bioethics and
Human Rights 2005) and the OECD (particularly their Report on Crea-
tion and Governance of Human Genetic Research Databases, in 2007 and
their Guidelines on Human Biobanks and Genetic Research Databases
2009). Similarly, there has been a great deal of progress by national
organisations in the development of governance frameworks for
biorepositories,which are seen as essential resources for global genomic
research. As examples, the National Cancer Institute of the National
Institutes of Health provided guidance on biobanks in 2006,21 as did
the international Human Genome Organisation in their Human Geno-
mic Databases Report in 2002. In Australia, the National Health and
Medical Research Council commissioned a Biobanks Information Paper
in 2010.
From the 1996 Human Genome Project Bermuda Declaration on-
wards, researchers themselves have also embraced the data sharing
movement.22 There is a realisation by researchers of the power of
shared data.23 This can, however, represent a tension with university
policies focusing on protection of intellectual property rights, engage-
ment with industry and formalisation of exchanges of materials.24
Despite this, it is widely understood that genomic research is aConsent: A Research Paradox?McGill Journal of Law Health 7, 85–120;.
18 Kaye J et al ‘Dynamic consent: a patient interface for twenty-ﬁrst century researchnet-
works’ European Journal of Human Genetics (2014) advance online publication 7 May
2014; doi: 10.1038/ejhg.2014.71 http://www.nature.com/ejhg/journal/vaop/ncurrent/
full/ejhg201471a.html.
19 Stein, D (2013) ‘Reforming Biobank Consent Policy: A Necessary Move Away from
Broad Consent Toward Dynamic Consent’ Genetic Testing and Molecular Biomarkers 17
(12) 855–856; Steinbekk, KMyskja B and Solberg B (2013). ‘BroadConsent versusDynam-
ic Consent in Biobanks Research: Is Passive Participation an Ethical Problem?’ European
Journal of Human Genetics 21, 897–902.
20 Kush R and Goldman M (2014). ‘Fostering Responsible Data Sharing through Stan-
dards’, New England Journal of Medicine 370(23):2163–2165.
21 National Cancer Institute, National Institutes of Health, US Department of Health and
Human Services (2006). First-Generation Guidelines for NCI-Supported BioRepositories,
http://biospecimens.cancer.gov/biorepositories/
First%20Generation%20Guidelines%20042006.pdf.
22 Sulston J and Ferry G (2003). The Common Thread, Corgi Books 165-9 and passim.
23 Joly Y, Dove ES, Knoppers BM, Bobrow M & Chalmers D (2012). ‘Data Sharing in the
Post-genomic World: the Experience of the International Cancer Genome Consortium
(ICGC) Data Access Compliance Ofﬁce (DACO)’, PLoS Computer Biology 8(7): e1002549.
doi:10.1371/journal.pcbi.1002549.
24 Caulﬁeld T, Harmon SHE and Joly Y (2012). ‘OpenScienceVersusCommercialization: a
Modern Research Conﬂict’, Genome Medicine 4:1.
128 D.R.C. Chalmers et al. / Applied & Translational Genomics 3 (2014) 116–119worldwide endeavour that requires the cooperation of researchers
working together between nations. However, the laws and guidelines
that govern such exchanges, including any subsequent use, differ
between countries, reﬂecting the cultural diversity that exists between
them. This presents a challenge, as there is no current international
agreement between nations at a high level that governs such exchange,
and national ethical guidelines are often developedwithout considering
the need for international harmonisation (with the exception of EU
member states).
The exchange of biological materials provides a useful reference
point. One of the features of the early stages of this biotechnology
revolution in the 1980s and 1990s was an increase in collaborations
between academia and industry, usually accompanied by transfer of
intellectual property rights and essential biological research materials.
Traditionally, these were freely shared and exchanged between
researchers, frequently without any type of legal documentation.25
The 1980s saw increasing engagement of universities with industry
and the development of national biotechnology strategies aimed at
commercialising research, coinciding with a move away from this
scientiﬁc norm of free and open sharing. University policies for engage-
ment with industry began to be directed towards protection of intellec-
tual property rights and their transfer to industry through assignment,
licensing and the creation of spin out companies. This university and
industry engagement saw the emergence of specialist technology
transfer ofﬁces.26.
There are great expectations that research in the ‘Genome Era’27 will
lead to the development of innovative products and processes in human
healthcare, agriculture, the environment and industry. Government
policy in many developed nations, expressly supports this research
direction. Although the impetus to secure intellectual property rights
remains strong, raw research data are increasingly shared amongst
researchers and uploaded on open access sites to maximise their
availability to other interested research groups.28 Leading research
funders, such as the United States National Institutes of Health (NIH)
Policy for Sharing of Data Obtained in NIH Supported or Conducted
Genome-Wide Association Studies have led initiatives to promote the
sharing of data by requiring that datasets remain available to all inves-
tigators, unencumbered by intellectual property claims.29 Similarly,
many public foundations such as theWelcome Trust and other signato-
ries to the Full Joint Statement by Funders of Health Research,30 have
joined these initiatives to promote the sharing of data generated in
research activities by publication of open access sites.
This modern open access culture, often referred to as the ‘research
commons’ aims to increase the volume and quality of research using
existing and new datasets.3125 Bennett A, Streitz W and Gaecel R (2007). ‘Speciﬁc Issues with Material Transfer
Agreements’, in Krattiger A, Mahoney R, Nelsen, L et al (eds) Intellectual Property Manage-
ment in Health and Agricultural Innovation: A Handbook of Best Practices. MIHR: Oxford; UK
and PIPRA: Davis, USA. Chapter 7.3: 697–706.
26 Rodriguez, V. (2007) Merton and Ziman's mode of science: the case of biological and
similarmaterial transfer agreements. Science and Public Policy 34: 355–363 Therewas also
a formalisation of exchanges of biologicalmaterials, throughmaterial transfer agreements.
27 Collins F (2010) The Language of Life: DNA and the Revolution in Personalized Medicine,
Harper Collins Publishers passim.
28 Toronto International Data Release Workshop Authors (2009). ‘Prepublication Data
Sharing’, Nature 461:168–170.
29 National Institutes of Health (NIH), Final NIH Statement on Sharing Research Data (26
February 2003), http://grants.nih.gov/grants/guide/notice-ﬁles/NOT-OD-03-032.html.
See also Glitter DM, ‘The Challenges of Achieving Open Source Sharing of Biobank Data’
(2010) 29(6) Biotechnology Law Report 623 at 627–628.
30 Karunakara U (2013). ‘Data Sharing in a Humanitarian Organization: The Experience
of Medecins Sans Frontieres’, PloS Medicine 10(12):e1001562.
31 Bubela T, Schoﬁeld PN, Ryan CD, Adams A and Einhorn D (2012). ‘Managing Intellec-
tual Property to Promote Pre-Competitive Research: the Mouse as a Model for Construct-
ing a Robust Research Commons’, Journal of Law, Information and Science 22:98–121.3. How to regulate sharing?
If the question on sharing data is more and more receiving an
afﬁrmative answer, because it is seen as an ethical and scientiﬁc imper-
ative, regulation will need to be reviewed and tested for ethical and
legal ‘ﬁtness-for-purpose’. In addition, the amount of data and the
frequency of access will expand exponentially, making this testing for
ethical and legal ‘ﬁtness-for-purpose’ essential. In this regard, three
organisations have taken leadership in promoting and developing data
sharing principles in the speciﬁc context of collaborative international
genomics research.32 These organisations, together with the Global
Alliance for Genomics and Health (GA4GH) have prepared a set of
guiding principles in a preliminary international data sharing Frame-
work of Conduct for Data Sharing. The Framework is a preliminary set
of standards for ethical and legal ‘ﬁtness-for-purpose’ in data sharing
and a focus to promote and maintain ongoing international
discussion.33
The challenges of responsible ethical and legal data exchange have
clear parallels with the development of regulatory frameworks for
biobanks. Challenges to traditional notions of individual consent, priva-
cy and public trust were acknowledged,34 and were particularly perti-
nent to large-scale population biobanks involving long-term tissue
and data storage; multiple research projects, often involving different
research teams in different countries; and research projects which
were not clearly deﬁned when the biobank was created. The establish-
ment of these large-scale biobanks around theworld led to the develop-
ment of policy statements by the OECD,35 practical guidelines from
funders, such as the US NCI36 and professional societies, such as
ISBER37 and much academic commentary debating the nature, form
and content of the instruments needed to regulate this activity. In addi-
tion, some biobanks, like the UK Biobank, developed their own ethics
and governance frameworks.38 Large-scale data sharing initiatives and re-
lated issues of ‘big data’ canbe seen from this perspective. The effort of the
GA4GH in its preliminary international Framework of Conduct for Data
Sharing is a major direction-setting initiative towards the development
of responsible ethical and legal standards by the research community.
The Framework incorporates four Foundational Principles for Responsible
Data Sharing {Respect Individuals, Families and Communities; Advance
Research and Scientiﬁc Knowledge; Promote Health, Wellbeing and the
Fair Distribution of Beneﬁts; and, Foster Trust, Integrity and Reciprocity)
and ten Core Elements for Responsible Data Sharing (Transparency; Ac-
countability; Engagement; Data Security and Quality; Privacy, Data Pro-
tection and Conﬁdentiality; Risk–Beneﬁt Analysis; Recognition and
Attribution; Sustainability; Education and Training; and, Accessibility
and Dissemination). These are standards and do not provide a single32 The international Public Population Project in Genomics (P3G), an international con-
sortium of large-scale genetic epidemiological studies and biobanks; the European Net-
work for Genetic and Genomic Epidemiology (ENGAGE), a research project to translate
data from large-scale epidemiological research initiatives into relevant clinical informa-
tion; and the Centre for Health, Law and Emerging Technologies (HeLEX).
33 This idea was promoted and adopted by the GA4GH from the article by Knoppers BM
et al (2011). ‘Towards a Data Sharing Code of Conduct for International Genomic Re-
search’, Genome Medicine 3:46–49. The “Code” was replaced in version 7 with
“Framework”.
34 Knoppers BM and Chadwick R (2006). ‘Human Genetic Research: Emerging Trends in
Ethics’, Nature Reviews Genetics 6:75–79.
35 Organisation for Economic Cooperation and Development, Guidelines on Human
Biobanks and Genetic Research Databases (OECD, 2009), www.oecd.org/dataoecd/41/47/
44054609.pdf.
36 See, for example, First-Generation Guidelines for NCI-Supported BioRepositories
April 2006, National Cancer Institute, National Institutes of Health, U.S. Department
of Health and Human Services http://biospecimens.cancer.gov/biorepositories/
First%20Generation%20Guidelines%20042006.pdf.
37 International Society for Biological and Environmental Repositories (ISBER). “Best
Practices for Repositories I: Collection, Storage, and Retrieval of Human Biological Mate-
rials for Research” (2005) 3 Cell Preservation Technology 1, 5-48.
38 UK Biobank, Ethics and Governance Framework, Version 3.0 2007 http://www.
ukbiobank.ac.uk/wp-content/uploads/2011/05/EGF20082.pdf?phpMyAdmin=
trmKQlYdjjnQIgJ%2CfAzikMhEnx6.
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and healthcare differences between countries.
4. Conclusions
If data sharing is no longer a question but a goal to be facilitated,
without compromising proper ethical standards, there is a need to
review the current data sharing practices to see whether any of the
pitfalls identiﬁed in the literature are in fact blocking sharing. As
noted, the potential pitfalls to data sharing are many and include
differences in more protective cultural approaches to clinical care
records and data. The GA4GH Framework of Conduct for Data Sharing
will, hopefully be a touchstone for developing and accelerating respon-
sible data sharing. Before increased regulation is proposed a study of the
actual legal blockages should be undertaken. There is a possibility, if not
likelihood, that blockages are, inmany instances,more of a practical and
cultural nature. On a practical level, ethical approval of research should
probably now include a standard reference to data sharing, with institu-
tions endorsing the GA4GH Framework of Conduct for Data Sharing. Inthe genome age of globalised research and electronic data linkage,
consent remains important but there must be a focus on the ‘gover-
nance’ approaches to the administration, management, custodianship,
access to data and monitoring of research, particularly large-scale
multi-centre international projects. The ethical ‘health’ of data sharing
practices and systems is highly dependent on researchers' primary
responsibilities under the national codes of research practice, the
second tier of review of research projects system and also, importantly,
on the integrity of the researchers themselves.39 Success can only be
achieved through the power of collaborative action with a shared
mission. TheGA4GHFramework for Conduct for data sharing potentially
has an important role to play in galvanising this effort.
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